Colinz Laboratories Limited (BOM:531210)

Market Cap	129.13M
Revenue (ttm)	65.28M
Net Income (ttm)	4.97M
Shares Out	2.52M
EPS (ttm)	1.97
PE Ratio	26.02
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,773
Average Volume	2,147
Open	50.95
Previous Close	48.82
Day's Range	50.95 - 51.26
52-Week Range	37.87 - 88.70
Beta	0.28
RSI	61.77
Earnings Date	Jul 30, 2025

About Colinz Laboratories

Colinz Laboratories Limited manufactures, markets, and trades in pharmaceutical formulations in India. The company offers pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, injectables, ointments, and creams, etc.; and specialized products for gynecology, cardiology, and gastroenterology, etc. Its allopathy products include oncology products, such as imitinib, erlotinib, letrozole, exemestane, bortezomib, fludarabine phosphate, doxorubicin, filgrastim, and pegylated liposome doxorubicin, etc.; antiritr...

• Industry: Pharmaceutical Preparations
• Founded: 1986
• Employees: 69
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 531210

Financial Performance

In 2024, Colinz Laboratories's revenue was 65.28 million, a decrease of -7.14% compared to the previous year's 70.30 million. Earnings were 4.97 million, an increase of 2.03%.